Skip to main content
Fig. 2 | Breast Cancer Research

Fig. 2

From: The effect of denosumab on disseminated tumor cells (DTCs) of breast cancer patients with neoadjuvant treatment: a GeparX translational substudy

Fig. 2

DTC-positivity at baseline and DTC-eradication after NACT ± denosumab. A Representative images of CK-positive DTCs in the bone marrow, stained by immunocytochemistry with the antibody A45-B/B3. B The bar chart shows the percentage of patients, being positive for DTCs in the bone marrow among the total cohort of the substudy and in the different study arm, i.e. in patients with NACT only and in patients with NACT + denosumab. C Bar charts showing the percentage of DTC-eradication in the bone marrow among the total cohort of the substudy and the different subtypes of breast cancer. P values according to the Fisher's Exact Test are indicated. HR: hormone receptor; HER2: human epidermal growth receptor 2; TNBC: triple-negative breast cancer

Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us